Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Assets: 2009-2025

Historic Assets for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $159.4 million.

  • Gyre Therapeutics' Assets rose 27.26% to $159.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.4 million, marking a year-over-year increase of 27.26%. This contributed to the annual value of $125.4 million for FY2024, which is 7.61% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Assets of $159.4 million as of Q3 2025, which was up 4.41% from $152.6 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Assets high stood at $159.4 million for Q3 2025, and its period low was $10.0 million during Q3 2023.
  • For the 3-year period, Gyre Therapeutics' Assets averaged around $99.4 million, with its median value being $122.0 million (2024).
  • In the last 5 years, Gyre Therapeutics' Assets plummeted by 85.13% in 2023 and then surged by 1,156.92% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Assets (Quarterly) stood at $55.7 million in 2021, then soared by 52.26% to $84.8 million in 2022, then spiked by 37.50% to $116.5 million in 2023, then climbed by 7.61% to $125.4 million in 2024, then climbed by 27.26% to $159.4 million in 2025.
  • Its last three reported values are $159.4 million in Q3 2025, $152.6 million for Q2 2025, and $129.8 million during Q1 2025.